{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T03:54:07Z","timestamp":1790308447477,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients undergoing lung transplantation (LTx) need administration of immunosuppressive therapy following the procedure to prevent graft rejection. However, these drugs are not exempt from potential risks. The development of cardiovascular risk factors and impaired renal function in the post-transplantation period are conditions that may be favoured by the use of calcineurin inhibitor (CNI) drugs which could have repercussions on the quality of life and the post-transplantation evolution. To evaluate the cardiovascular and renal toxicity following the administration of CNI as maintenance immunosuppression in lung transplant recipients (LTRs) we reviewed a total number of 165 patients undergoing LTx between 01\/01\/2015 and 08\/12\/2018. They were divided into two groups according to the CNI drug administrated: cyclosporine (CsA-group) with 11 patients or tacrolimus (Tac-group), with 154 patients. We evaluated the de novo occurrence of arterial hypertension (HTN), diabetes mellitus (DM), hyperlipidemia and impaired renal function after initiation of CNI administration. In addition to that, the time until each of these events was assessed. A higher rate for developing HTN (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and impaired renal function (<jats:italic>p<\/jats:italic>\u2009=\u20090.047) was observed within the CsA-group. The new onset of hyperlipidemia was similar between both CNI groups and de novo appearance of DM was only documented in those LTRs receiving tacrolimus. In this LTRs retrospective study, it was observed that having\u2009\u2265\u20094 tacrolimus trough levels above the upper limit of the proposed interval for each specific post-LTx period was associated with an increased risk for developing renal impairment. No other statistically significant association was found between supratherapeutic CNIs blood levels and the evaluated toxicities.<\/jats:p>","DOI":"10.1038\/s41598-022-25445-2","type":"journal-article","created":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T16:10:38Z","timestamp":1670515838000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Calcineurin inhibitors\u2019 impact on cardiovascular and renal function, a descriptive study in lung transplant recipients from the North of Spain"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7989-6951","authenticated-orcid":false,"given":"Rita","family":"Nogueiras-\u00c1lvarez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8161-0462","authenticated-orcid":false,"given":"V\u00edctor Manuel","family":"Mora-Cuesta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"Cifri\u00e1n-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6960-6831","authenticated-orcid":false,"given":"Mar\u00eda \u00c1ngeles","family":"de Cos-Coss\u00edo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda del Mar","family":"Garc\u00eda-S\u00e1iz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,8]]},"reference":[{"issue":"2","key":"25445_CR1","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.healun.2015.07.003","volume":"35","author":"A Seiler","year":"2016","unstructured":"Seiler, A. et al. A systematic review of health-related quality of life and psychological outcomes after lung transplantation. J. Heart Lung Transplant. 35(2), 195\u2013202. https:\/\/doi.org\/10.1016\/j.healun.2015.07.003 (2016).","journal-title":"J. Heart Lung Transplant."},{"issue":"10","key":"25445_CR2","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.healun.2019.08.001.PMID:31548030","volume":"38","author":"DC Chambers","year":"2019","unstructured":"Chambers, D. C. et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart\u2013lung transplantation Report\u20142019; focus theme: Donor and recipient size match. J. Heart Lung Transplant. 38(10), 1042\u20131055. https:\/\/doi.org\/10.1016\/j.healun.2019.08.001.PMID:31548030 (2019).","journal-title":"J. Heart Lung Transplant."},{"issue":"8","key":"25445_CR3","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.healun.2012.03.008","volume":"31","author":"H Treede","year":"2012","unstructured":"Treede, H. et al. Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: Results of a prospective, randomized international trial in lung transplantation. J. Heart Lung Transplant. Off. Publ. Int. Soc. Heart Transplant. 31(8), 797\u2013804. https:\/\/doi.org\/10.1016\/j.healun.2012.03.008 (2012).","journal-title":"J. Heart Lung Transplant. Off. Publ. Int. Soc. Heart Transplant."},{"issue":"2","key":"25445_CR4","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.bpa.2017.05.006","volume":"31","author":"J Costa","year":"2017","unstructured":"Costa, J., Benvenuto, L. J. & Sonett, J. R. Long-term outcomes and management of lung transplant recipients. Best Pract. Res. Clin. Anaesthesiol. 31(2), 285\u2013297. https:\/\/doi.org\/10.1016\/j.bpa.2017.05.006 (2017).","journal-title":"Best Pract. Res. Clin. Anaesthesiol."},{"issue":"2","key":"25445_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.trre.2013.01.004","volume":"27","author":"G Opelz","year":"2013","unstructured":"Opelz, G. et al. The collaborative transplant study registry. Transplant. Rev. 27(2), 43\u201345. https:\/\/doi.org\/10.1016\/j.trre.2013.01.004 (2013).","journal-title":"Transplant. Rev."},{"issue":"9","key":"25445_CR6","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1034\/j.1600-6143.2002.20902.x","volume":"2","author":"LW Miller","year":"2002","unstructured":"Miller, L. W. Cardiovascular toxicities of immunosuppressive agents: CV toxicities of immunosuppressive agents. Am. J. Transplant. 2(9), 807\u2013818. https:\/\/doi.org\/10.1034\/j.1600-6143.2002.20902.x (2002).","journal-title":"Am. J. Transplant."},{"issue":"10","key":"25445_CR7","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.healun.2016.09.001","volume":"35","author":"RD Yusen","year":"2016","unstructured":"Yusen, R. D. et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-third adult lung and heart-lung transplant report-2016; focus theme: Primary diagnostic indications for transplant. J. Heart Lung Transplant. Off. Publ. Int. Soc. Heart Transplant. 35(10), 1170\u20131184. https:\/\/doi.org\/10.1016\/j.healun.2016.09.001 (2016).","journal-title":"J. Heart Lung Transplant. Off. Publ. Int. Soc. Heart Transplant."},{"issue":"1","key":"25445_CR8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.14503\/THIJ-18-6749","volume":"46","author":"A Rana","year":"2019","unstructured":"Rana, A. & Godfrey, E. L. Outcomes in solid-organ transplantation: Success and stagnation. Tex. Heart Inst. J. 46(1), 75\u201376. https:\/\/doi.org\/10.14503\/THIJ-18-6749 (2019).","journal-title":"Tex. Heart Inst. J."},{"issue":"2","key":"25445_CR9","first-page":"183","volume":"28","author":"LD Luca","year":"2015","unstructured":"Luca, L. D., Westbrook, R. & Tsochatzis, E. A. Metabolic and cardiovascular complications in the liver transplant recipient. Ann. Gastroenterol. 28(2), 183\u2013192 (2015).","journal-title":"Ann. Gastroenterol."},{"issue":"1","key":"25445_CR10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1053\/j.ackd.2019.08.006","volume":"27","author":"SS Farouk","year":"2020","unstructured":"Farouk, S. S. & Rein, J. L. The many faces of calcineurin inhibitor toxicity\u2014What the FK?. Adv. Chronic Kidney Dis. 27(1), 56\u201366. https:\/\/doi.org\/10.1053\/j.ackd.2019.08.006 (2020).","journal-title":"Adv. Chronic Kidney Dis."},{"issue":"28","key":"25445_CR11","doi-asserted-by":"publisher","first-page":"6416","DOI":"10.3748\/wjg.v22.i28.6416","volume":"22","author":"M Jim\u00e9nez-P\u00e9rez","year":"2016","unstructured":"Jim\u00e9nez-P\u00e9rez, M., Gonz\u00e1lez-Grande, R., Omonte Guzm\u00e1n, E., Amo Trillo, V. & Rodrigo L\u00f3pez, J. M. Metabolic complications in liver transplant recipients. World J. Gastroenterol. 22(28), 6416\u20136423. https:\/\/doi.org\/10.3748\/wjg.v22.i28.6416 (2016).","journal-title":"World J. Gastroenterol."},{"issue":"8","key":"25445_CR12","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1097\/01.TP.0000062837.99400.60","volume":"75","author":"T Gonwa","year":"2003","unstructured":"Gonwa, T. et al. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: Results at 6 months. Transplantation 75(8), 1213\u20131220. https:\/\/doi.org\/10.1097\/01.TP.0000062837.99400.60 (2003).","journal-title":"Transplantation"},{"issue":"2","key":"25445_CR13","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1210\/endrev\/bnaa030","volume":"42","author":"M Bhat","year":"2021","unstructured":"Bhat, M., Usmani, S. E., Azhie, A. & Woo, M. Metabolic consequences of solid organ transplantation. Endocr. Rev. 42(2), 171\u2013197. https:\/\/doi.org\/10.1210\/endrev\/bnaa030 (2021).","journal-title":"Endocr. Rev."},{"issue":"1","key":"25445_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/0735-1097(93)90814-h","volume":"22","author":"LW Miller","year":"1993","unstructured":"Miller, L. W., Schlant, R. C., Kobashigawa, J., Kubo, S. & Renlund, D. G. Task force 5: Complications. J. Am. Coll. Cardiol. 22(1), 41\u201354. https:\/\/doi.org\/10.1016\/0735-1097(93)90814-h (1993).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"10","key":"25445_CR15","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.healun.2016.08.017","volume":"35","author":"LH Lund","year":"2016","unstructured":"Lund, L. H. et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-third adult heart transplantation report-2016; Focus theme: Primary diagnostic indications for transplant. J. Heart Lung Transplant. Off. Publ. Int. Soc. Heart Transplant. 35(10), 1158\u20131169. https:\/\/doi.org\/10.1016\/j.healun.2016.08.017 (2016).","journal-title":"J. Heart Lung Transplant. Off. Publ. Int. Soc. Heart Transplant."},{"issue":"1","key":"25445_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0272-6386(99)70101-0","volume":"34","author":"MR Weir","year":"1999","unstructured":"Weir, M. R. & Fink, J. C. Risk for posttransplant Diabetes mellitus with current immunosuppressive medications. Am. J. Kidney Dis. Off. J. Natl. Kidney Found. 34(1), 1\u201313. https:\/\/doi.org\/10.1016\/s0272-6386(99)70101-0 (1999).","journal-title":"Am. J. Kidney Dis. Off. J. Natl. Kidney Found."},{"issue":"2","key":"25445_CR17","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3109\/07435800.2015.1094088","volume":"41","author":"W Cheungpasitporn","year":"2016","unstructured":"Cheungpasitporn, W., Thongprayoon, C., Harindhanavudhi, T., Edmonds, P. J. & Erickson, S. B. Hypomagnesemia linked to new-onset diabetes mellitus after kidney transplantation: A systematic review and meta-analysis. Endocr. Res. 41(2), 142\u2013147. https:\/\/doi.org\/10.3109\/07435800.2015.1094088 (2016).","journal-title":"Endocr. Res."},{"issue":"6","key":"25445_CR18","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1002\/dmrr.1206","volume":"27","author":"M Rodr\u00edguez-Mor\u00e1n","year":"2011","unstructured":"Rodr\u00edguez-Mor\u00e1n, M. & Guerrero-Romero, F. Insulin secretion is decreased in non-diabetic individuals with hypomagnesaemia. Diabetes Metab. Res. Rev. 27(6), 590\u2013596. https:\/\/doi.org\/10.1002\/dmrr.1206 (2011).","journal-title":"Diabetes Metab. Res. Rev."},{"key":"25445_CR19","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2147\/DMSO.S19027","volume":"4","author":"P-TT Pham","year":"2011","unstructured":"Pham, P.-T.T., Pham, P.-M.T., Pham, S. V., Pham, P.-A.T. & Pham, P.-C.T. New onset diabetes after transplantation (NODAT): An overview. Diabetes Metab. Syndr. Obes. Targets Ther. 4, 175\u2013186. https:\/\/doi.org\/10.2147\/DMSO.S19027 (2011).","journal-title":"Diabetes Metab. Syndr. Obes. Targets Ther."},{"issue":"3","key":"25445_CR20","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1177\/2042018816641580","volume":"7","author":"O Bamgbola","year":"2016","unstructured":"Bamgbola, O. Metabolic consequences of modern immunosuppressive agents in solid organ transplantation. Ther. Adv. Endocrinol. Metab. 7(3), 110\u2013127. https:\/\/doi.org\/10.1177\/2042018816641580 (2016).","journal-title":"Ther. Adv. Endocrinol. Metab."},{"issue":"6","key":"25445_CR21","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1097\/00007890-199306000-00023","volume":"55","author":"SC Textor","year":"1993","unstructured":"Textor, S. C. et al. Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. Transplantation 55(6), 1332\u20131338. https:\/\/doi.org\/10.1097\/00007890-199306000-00023 (1993).","journal-title":"Transplantation"},{"issue":"1","key":"25445_CR22","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1053\/j.ackd.2005.11.001","volume":"13","author":"D Williams","year":"2006","unstructured":"Williams, D. & Haragsim, L. Calcineurin nephrotoxicity. Adv. Chronic Kidney Dis. 13(1), 47\u201355. https:\/\/doi.org\/10.1053\/j.ackd.2005.11.001 (2006).","journal-title":"Adv. Chronic Kidney Dis."},{"issue":"8","key":"25445_CR23","doi-asserted-by":"publisher","first-page":"717","DOI":"10.21037\/atm-20-7644","volume":"9","author":"L Jing","year":"2021","unstructured":"Jing, L. et al. Acute kidney injury after lung transplantation: A narrative review. Ann. Transl. Med. 9(8), 717. https:\/\/doi.org\/10.21037\/atm-20-7644 (2021).","journal-title":"Ann. Transl. Med."},{"issue":"5","key":"25445_CR24","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00228-017-2204-8","volume":"73","author":"MA Sikma","year":"2017","unstructured":"Sikma, M. A. et al. High tacrolimus blood concentrations early after lung transplantation and the risk of kidney injury. Eur. J. Clin. Pharmacol. 73(5), 573\u2013580. https:\/\/doi.org\/10.1007\/s00228-017-2204-8 (2017).","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"6","key":"25445_CR25","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1016\/j.transproceed.2021.05.005","volume":"53","author":"CM McPheeters","year":"2021","unstructured":"McPheeters, C. M. et al. Calcineurin inhibitor-based maintenance immunosuppression in lung transplant recipients: Optimal serum levels for managing acute rejection and renal function. Transplant. Proc. 53(6), 1998\u20132003. https:\/\/doi.org\/10.1016\/j.transproceed.2021.05.005 (2021).","journal-title":"Transplant. Proc."},{"issue":"9","key":"25445_CR26","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1111\/j.1600-6143.2008.02342.x","volume":"8","author":"C Lefaucheur","year":"2008","unstructured":"Lefaucheur, C. et al. Renal histopathological lesions after lung transplantation in patients with cystic fibrosis. Am. J. Transplant. 8(9), 1901\u20131910. https:\/\/doi.org\/10.1111\/j.1600-6143.2008.02342.x (2008).","journal-title":"Am. J. Transplant."},{"issue":"4","key":"25445_CR27","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1097\/01.ftd.0000170029.36573.a0","volume":"27","author":"H Zahir","year":"2005","unstructured":"Zahir, H. et al. Population pharmacokinetic estimation of tacrolimus apparent clearance in adult liver transplant recipients. Ther. Drug Monit. 27(4), 422\u2013430. https:\/\/doi.org\/10.1097\/01.ftd.0000170029.36573.a0 (2005).","journal-title":"Ther. Drug Monit."},{"issue":"2","key":"25445_CR28","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/0009-9120(96)00001-x","volume":"29","author":"N Rifai","year":"1996","unstructured":"Rifai, N., Chao, F.-F., Pham, Q., Thiessen, J. & Soldin, S. J. The role of lipoproteins in the transport and uptake of cyclosporine and dihydro-tacrolimus into HepG2 and JURKAT cell lines. Clin. Biochem. 29(2), 149\u2013155. https:\/\/doi.org\/10.1016\/0009-9120(96)00001-x (1996).","journal-title":"Clin. Biochem."},{"issue":"1","key":"25445_CR29","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.transproceed.2019.10.032","volume":"52","author":"F Woll","year":"2020","unstructured":"Woll, F. et al. Characteristics and outcomes of lung transplant candidates with preexisting renal dysfunction. Transplant. Proc. 52(1), 302\u2013308. https:\/\/doi.org\/10.1016\/j.transproceed.2019.10.032 (2020).","journal-title":"Transplant. Proc."},{"issue":"11","key":"25445_CR30","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.healun.2007.08.006","volume":"26","author":"DP Mason","year":"2007","unstructured":"Mason, D. P. et al. Dialysis after lung transplantation: Prevalence, risk factors and outcome. J. Heart Lung Transplant. Off. Publ. Int. Soc. Heart Transplant. 26(11), 1155\u20131162. https:\/\/doi.org\/10.1016\/j.healun.2007.08.006 (2007).","journal-title":"J. Heart Lung Transplant. Off. Publ. Int. Soc. Heart Transplant."},{"issue":"7A","key":"25445_CR31","doi-asserted-by":"publisher","first-page":"21S","DOI":"10.1016\/s0041-1345(99)00788-5","volume":"31","author":"NA Undre","year":"1999","unstructured":"Undre, N. A., Stevenson, P. & Sch\u00e4fer, A. Pharmacokinetics of tacrolimus: Clinically relevant aspects. Transplant. Proc. 31(7A), 21S-24S. https:\/\/doi.org\/10.1016\/s0041-1345(99)00788-5 (1999).","journal-title":"Transplant. Proc."},{"issue":"2","key":"25445_CR32","doi-asserted-by":"publisher","first-page":"374","DOI":"10.2215\/CJN.03791106","volume":"2","author":"J Schiff","year":"2007","unstructured":"Schiff, J., Cole, E. & Cantarovich, M. Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin. J. Am. Soc. Nephrol. 2(2), 374\u2013384. https:\/\/doi.org\/10.2215\/CJN.03791106 (2007).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"1","key":"25445_CR33","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40780-022-00256-9.PMID:36180948","volume":"8","author":"Y Katada","year":"2022","unstructured":"Katada, Y. et al. Association between time in therapeutic range of tacrolimus blood concentration and acute rejection within the first three months after lung transplantation. J. Pharm. Health Care Sci. 8(1), 25. https:\/\/doi.org\/10.1186\/s40780-022-00256-9.PMID:36180948 (2022).","journal-title":"J. Pharm. Health Care Sci."},{"issue":"3","key":"25445_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0059634","volume":"8","author":"S Sanquer","year":"2013","unstructured":"Sanquer, S. et al. Expression of calcineurin activity after lung transplantation: A 2-year follow-up. PLoS ONE 8(3), e59634. https:\/\/doi.org\/10.1371\/journal.pone.0059634 (2013) (Epub 2013 Mar 25).","journal-title":"PLoS ONE"},{"key":"25445_CR35","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.ejcts.2006.09.027","volume":"30","author":"I Al-Githmi","year":"2006","unstructured":"Al-Githmi, I. et al. Bronchiolitis obliterans following lung transplantation. Eur. J. Cardiothorac. Surg. 30, 846\u2013851 (2006).","journal-title":"Eur. J. Cardiothorac. Surg."},{"issue":"7520","key":"25445_CR36","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1136\/bmj.38569.471007.AE","volume":"331","author":"AC Webster","year":"2005","unstructured":"Webster, A. C., Woodroffe, R. C., Taylor, R. S., Chapman, J. R. & Craig, J. C. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: Meta-analysis and meta-regression of randomised trial data. BMJ 331(7520), 810. https:\/\/doi.org\/10.1136\/bmj.38569.471007.AE (2005).","journal-title":"BMJ"},{"issue":"3","key":"25445_CR37","doi-asserted-by":"publisher","first-page":"269","DOI":"10.5301\/jn.5000174","volume":"25","author":"EJ Hoorn","year":"2012","unstructured":"Hoorn, E. J. et al. Pathogenesis of calcineurin inhibitor-induced hypertension. J. Nephrol. 25(3), 269\u2013275 (2012).","journal-title":"J. Nephrol."},{"issue":"6","key":"25445_CR38","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.4103\/1319-2442.248292","volume":"29","author":"A Azarfar","year":"2018","unstructured":"Azarfar, A. et al. Comparison of tacrolimus and cyclosporine for immunosuppression after renal transplantation: An updated systematic review and meta-analysis. Saudi J. Kidney Dis. Transplant. Off. Publ. Saudi Cent. Organ. Transplant. Saudi Arab. 29(6), 1376\u20131385. https:\/\/doi.org\/10.4103\/1319-2442.248292 (2018).","journal-title":"Saudi J. Kidney Dis. Transplant. Off. Publ. Saudi Cent. Organ. Transplant. Saudi Arab."},{"issue":"10","key":"25445_CR39","doi-asserted-by":"publisher","first-page":"4181","DOI":"10.1016\/j.transproceed.2009.09.069","volume":"41","author":"P Seymen","year":"2009","unstructured":"Seymen, P., Yildiz, M., T\u00fcrkmen, M. F., Titiz, M. I. & Seymen, H. O. Effects of cyclosporine-tacrolimus switching in posttransplantation hyperlipidemia on high-density lipoprotein 2\/3, lipoprotein a1\/b, and other lipid parameters. Transplant. Proc. 41(10), 4181\u20134183. https:\/\/doi.org\/10.1016\/j.transproceed.2009.09.069 (2009).","journal-title":"Transplant. Proc."},{"issue":"2","key":"25445_CR40","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1093\/ndt\/gfr238","volume":"27","author":"K Claes","year":"2012","unstructured":"Claes, K. et al. Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: Evidence from the Symphony study. Nephrol. Dial. Transplant. 27(2), 850\u2013857. https:\/\/doi.org\/10.1093\/ndt\/gfr238 (2012).","journal-title":"Nephrol. Dial. Transplant."},{"issue":"4","key":"25445_CR41","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1097\/01.tp.0000231711.82193.41","volume":"82","author":"A Roy","year":"2006","unstructured":"Roy, A. et al. Tacrolimus as intervention in the treatment of hyperlipidemia after liver transplant. Transplantation 82(4), 494\u2013500. https:\/\/doi.org\/10.1097\/01.tp.0000231711.82193.41 (2006).","journal-title":"Transplantation"},{"issue":"3","key":"25445_CR42","doi-asserted-by":"publisher","first-page":"e810","DOI":"10.1097\/MJT.0000000000000150","volume":"23","author":"J-Y Liu","year":"2016","unstructured":"Liu, J.-Y. et al. Tacrolimus versus cyclosporine as primary immunosuppressant after renal transplantation: A meta-analysis and economics evaluation. Am. J. Ther. 23(3), e810-824. https:\/\/doi.org\/10.1097\/MJT.0000000000000150 (2016).","journal-title":"Am. J. Ther."},{"issue":"5","key":"25445_CR43","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1016\/j.transproceed.2008.11.016","volume":"41","author":"Y Fan","year":"2009","unstructured":"Fan, Y., Xiao, Y.-B. & Weng, Y.-G. Tacrolimus versus cyclosporine for adult lung transplant recipients: A meta-analysis. Trans-Plant Proc. 41(5), 1821\u20131824 (2009).","journal-title":"Trans-Plant Proc."},{"issue":"2","key":"25445_CR44","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/tri.13540","volume":"33","author":"J Raskin","year":"2020","unstructured":"Raskin, J. et al. Mortality after lung trans-plantation: A single-centre cohort analysis. Transpl. Int. Off. J. Eur. Soc. Organ. Transplant. 33(2), 130\u2013141. https:\/\/doi.org\/10.1111\/tri.13540 (2020).","journal-title":"Transpl. Int. Off. J. Eur. Soc. Organ. Transplant."},{"issue":"5","key":"25445_CR45","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1097\/00007890-200203150-00021","volume":"73","author":"F Vincenti","year":"2002","unstructured":"Vincenti, F., Jensik, S. C., Filo, R. S., Miller, J. & Pirsch, J. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: Evidence for improved allograft survival at five years. Transplantation 73(5), 775\u2013782. https:\/\/doi.org\/10.1097\/00007890-200203150-00021 (2002).","journal-title":"Transplantation"},{"issue":"2","key":"25445_CR46","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s11255-007-9266-y","volume":"40","author":"DN Perrea","year":"2008","unstructured":"Perrea, D. N. et al. Correlation between lipid abnormalities and immunosuppressive therapy in renal transplant recipients with stable renal function. Int. Urol. Nephrol. 40(2), 521\u2013527. https:\/\/doi.org\/10.1007\/s11255-007-9266-y (2008).","journal-title":"Int. Urol. Nephrol."},{"key":"25445_CR47","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ijsu.2017.12.037","volume":"51","author":"JL Song","year":"2018","unstructured":"Song, J. L. et al. Higher tacrolimus blood concentration is related to increased risk of post-transplantation diabetes mellitus after living donor liver transplantation. Int. J. Surg. 51, 17\u201323. https:\/\/doi.org\/10.1016\/j.ijsu.2017.12.037 (2018).","journal-title":"Int. J. Surg."},{"issue":"6","key":"25445_CR48","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1097\/TP.0b013e3182461288","volume":"93","author":"PA Jacobson","year":"2012","unstructured":"Jacobson, P. A. et al. Genetic and clinical determinants of early, acute calcineurin inhibitor-related nephrotoxicity: Results from a kidney trans-plant consortium. Transplantation 93(6), 624\u2013631. https:\/\/doi.org\/10.1097\/TP.0b013e3182461288 (2012).","journal-title":"Transplantation"},{"issue":"1","key":"25445_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1399-0012.2007.00739.x","volume":"22","author":"SM Flechner","year":"2008","unstructured":"Flechner, S. M., Kobashigawa, J. & Klintmalm, G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: Focus on improving renal function and nephrotoxicity. Clin. Transplant. 22(1), 1\u201315. https:\/\/doi.org\/10.1111\/j.1399-0012.2007.00739.x (2008).","journal-title":"Clin. Transplant."},{"issue":"3","key":"25445_CR50","doi-asserted-by":"publisher","first-page":"73","DOI":"10.5500\/wjt.v5.i3.73","volume":"5","author":"L Zsom","year":"2015","unstructured":"Zsom, L., Wagner, L. & F\u00fcl\u00f6p, T. Minimization vs tailoring: Where do we stand with personalized immunosuppression during renal transplantation in 2015?. World J. Transplant. 5(3), 73\u201380. https:\/\/doi.org\/10.5500\/wjt.v5.i3.73 (2015).","journal-title":"World J. Transplant."},{"issue":"7","key":"25445_CR51","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1097\/TP.0b013e3181cbac2d","volume":"89","author":"L Gullestad","year":"2010","unstructured":"Gullestad, L. et al. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: A multicentre, randomized trial. Transplantation 89(7), 864\u2013872. https:\/\/doi.org\/10.1097\/TP.0b013e3181cbac2d (2010).","journal-title":"Transplantation"},{"issue":"2","key":"25445_CR52","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/TP.0b013e3181927a41","volume":"87","author":"FP Schena","year":"2009","unstructured":"Schena, F. P. et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 87(2), 233\u2013242. https:\/\/doi.org\/10.1097\/TP.0b013e3181927a41 (2009).","journal-title":"Transplantation"},{"issue":"6","key":"25445_CR53","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1111\/ajt.15251","volume":"19","author":"J Gottlieb","year":"2019","unstructured":"Gottlieb, J. et al. A randomized trial of everolimus-based quadruple therapy vs standard triple therapy early after lung transplantation. Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg. 19(6), 1759\u20131769. https:\/\/doi.org\/10.1111\/ajt.15251 (2019).","journal-title":"Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg."},{"issue":"10","key":"25445_CR54","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1097\/TP.0000000000002769","volume":"103","author":"N Montero","year":"2019","unstructured":"Montero, N. et al. Mammalian target of rapamycin inhibitors combined with calcineurin inhibitors as initial immunosuppression in renal transplantation: A meta-analysis. Transplantation 103(10), 2031\u20132056. https:\/\/doi.org\/10.1097\/TP.0000000000002769 (2019).","journal-title":"Transplantation"},{"issue":"10","key":"25445_CR55","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1097\/01.tp.0000123082.31092.53","volume":"77","author":"PG Dean","year":"2004","unstructured":"Dean, P. G. et al. Wound-healing complications after kidney transplantation: A prospective, randomized comparison of sirolimus and tacrolimus. Transplantation 77(10), 1555\u20131561. https:\/\/doi.org\/10.1097\/01.tp.0000123082.31092.53 (2004).","journal-title":"Transplantation"},{"issue":"4","key":"25445_CR56","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1097\/TP.0000000000001392","volume":"101","author":"P Ueno","year":"2017","unstructured":"Ueno, P. et al. Wound healing complications in kidney transplant recipients receiving everolimus. Transplantation 101(4), 844\u2013850. https:\/\/doi.org\/10.1097\/TP.0000000000001392 (2017).","journal-title":"Transplantation"},{"issue":"1","key":"25445_CR57","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.transproceed.2020.05.021","volume":"53","author":"O Gilad","year":"2021","unstructured":"Gilad, O. et al. Metabolic and renal effects of mammalian target of rapamycin inhibitors treatment after liver transplantation: Real-life single-center experience. Transplant. Proc. 53(1), 221\u2013227. https:\/\/doi.org\/10.1016\/j.transproceed.2020.05.021 (2021).","journal-title":"Transplant. Proc."},{"issue":"2","key":"25445_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.trre.2021.100610","volume":"35","author":"HE Braithwaite","year":"2021","unstructured":"Braithwaite, H. E., Darley, D. R., Brett, J., Day, R. O. & Carland, J. E. Identifying the association between tacrolimus exposure and toxicity in heart and lung transplant recipients: A systematic review. Transplant. Rev. Orlando Fla. 35(2), 100610. https:\/\/doi.org\/10.1016\/j.trre.2021.100610 (2021).","journal-title":"Transplant. Rev. Orlando Fla."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-25445-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-25445-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-25445-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T16:12:06Z","timestamp":1670515926000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-25445-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,8]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["25445"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-25445-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,8]]},"assertion":[{"value":"7 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21207"}}